NASDAQ:AEON AEON Biopharma (AEON) Stock Price, News & Analysis $0.26 0.00 (-0.76%) Closing price 04:00 PM EasternExtended Trading$0.26 +0.00 (+0.15%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About AEON Biopharma Stock (NASDAQ:AEON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AEON Biopharma alerts:Sign Up Key Stats Today's Range$0.26▼$0.2750-Day Range$0.19▼$0.3352-Week Range$0.18▼$1.45Volume310,652 shsAverage Volume2.33 million shsMarket Capitalization$13.05 millionP/E Ratio1.45Dividend YieldN/APrice Target$1.33Consensus RatingModerate Buy Company Overview AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. The company’s lead product candidate, ABP-450, is an injectable botulinum toxin type A complex being developed for disorders involving muscle contraction and nerve signaling. AEON has primarily focused its clinical development programs on chronic migraine and cervical dystonia, a condition characterized by involuntary neck-muscle contractions. The company has also evaluated potential applications in other therapeutic areas, with the goal of expanding botulinum toxin beyond its established cosmetic uses. Based in Irvine, California, AEON Biopharma became a publicly traded company following a business combination with Priveterra Acquisition Corp. in 2023. Marc Forth serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More AEON Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreAEON MarketRank™: AEON Biopharma scored higher than 79% of companies evaluated by MarketBeat, and ranked 114th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAEON Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAEON Biopharma has a consensus price target of $1.33, representing about 409.7% upside from its current price of $0.26.Amount of Analyst CoverageAEON Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about AEON Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AEON Biopharma is 1.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.18.Price to Earnings Ratio vs. SectorThe P/E ratio of AEON Biopharma is 1.45, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 214.73.Read more about AEON Biopharma's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AEON. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAEON Biopharma does not currently pay a dividend.Dividend GrowthAEON Biopharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest14 people have searched for AEON on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $241,500.00 in company stock, which represents 1.8507% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AEON Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $241,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders9.40% of the stock of AEON Biopharma is held by insiders.Percentage Held by Institutions22.78% of the stock of AEON Biopharma is held by institutions.Read more about AEON Biopharma's insider trading history. Receive AEON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEON Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AEON Stock News HeadlinesAEON Reports Comparable Forced Degradation Results For ABP-450 In Pilot Study; Stock UpSeptember 10, 2026 | rttnews.comAEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®September 9, 2026 | globenewswire.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents.September 28 at 1:00 AM | Brownstone Research (Ad)AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) ConferenceAugust 31, 2026 | globenewswire.comAEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory OfficerAugust 24, 2026 | globenewswire.comAEON Flat on BOTOX DevelopmentsAugust 19, 2026 | baystreet.caAEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®August 19, 2026 | globenewswire.comAEON Biopharma Inc: AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 13, 2026 | finanznachrichten.deSee More Headlines AEON Stock Analysis - Frequently Asked Questions How have AEON shares performed this year? AEON Biopharma's stock was trading at $1.10 at the beginning of the year. Since then, AEON shares have decreased by 76.2% and is now trading at $0.2616. When did AEON Biopharma's stock split? Shares of AEON Biopharma reverse split on Wednesday, February 26th 2025.The 1-72 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did AEON Biopharma IPO? AEON Biopharma (AEON) raised $75 million in an IPO on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. How do I buy shares of AEON Biopharma? Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AEON Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Today9/28/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AEON Previous SymbolNASDAQ:AEON CIK1837607 Webwww.aeonbiopharma.com Phone(949) 354-6499FaxN/AEmployees8Year Founded2012Price Target and Rating Average Price Target for AEON Biopharma$1.33 High Price Target$1.80 Low Price Target$1.00 Potential Upside/Downside+409.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.42) Trailing P/E Ratio1.45 Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.63 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-994.63% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.06Miscellaneous Outstanding Shares49,883,000Free Float74,373,000Market Cap$13.05 million OptionableNot Optionable Beta0.65 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AEON) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
